BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 65223)

  • 1. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclocytidine chemotherapy for malignant melanoma.
    McKelvey EM; Hewlett JS; Thigpen T; Whitecar J
    Cancer Treat Rep; 1978 Mar; 62(3):469-71. PubMed ID: 77191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
    Rudolf Z; Plesnicar S
    Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II evaluation of cyclocytidine.
    Burgess MA; Bodey GP; Minow RA; Gottlieb JA
    Cancer Treat Rep; 1977; 61(3):437-43. PubMed ID: 68828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Photosensitization with DTIC therapy in metastatic malignant melanoma].
    Bolling R; Meyer-Hamme S; Schauder S
    Hautarzt; 1980 Nov; 31(11):602-5. PubMed ID: 7451142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
    Friedman MA; Kaufman DA; Williams JE; Resser KJ; Rosenbaum EH; Cohen RJ; Glassberg AB; Blume MR; Gershow J; Chan EY
    Cancer Treat Rep; 1979 Mar; 63(3):493-5. PubMed ID: 371802
    [No Abstract]   [Full Text] [Related]  

  • 13. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
    Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
    Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of malignant melanoma using DTIC].
    Zaumseil RP; Fiedler H; Lübbe D
    Dermatol Monatsschr; 1977 Nov; 163(11):905-14. PubMed ID: 590586
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
    Kleeberg UR; Schreml W
    Dtsch Med Wochenschr; 1976 Jun; 101(23):890-4. PubMed ID: 1269431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.